reports
QuickView: An eye on commercialisation
Ocata has completed enrolment and published encouraging results in its Phase I/II trial of stem cell therapy in both dry age-related macular degeneration (AMD) and Stargardt’s macular degeneration (SMD). It is pursuing the quicker orphan drug approval process of SMD and the large potential market of AMD by beginning an AMD Phase II trial and a pivotal trial in SMD. It has also secured a licensing agreement to use induced pluripotent stem cells (iPSC) as a platform for differentiating ocular ti...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.